我们调查了质量控制 (QC) 计划对晚期卵巢癌的管理策略、手术完整性和临床结果的影响。对 2005 年 1 月至 2019 年 12 月的医疗记录进行回顾性审查，确定了 129 名晚期卵巢癌患者。在实施质量控制计划之前和之后，病例被分为第一组（2005-2013年）和第二组（2014-2019年）。比较包括临床病理学变量、手术细节、复发和生存结果。 在第 2 组 (n=44) 中，实施 QC 计划后，初次减瘤手术 (PDS) 减少（87.1% 对比 63.6%），间隔减瘤手术 (IDS) 增加（12.9% vs. 36.4%），表明手术策略的转变。第 2 组中 PDS 的最佳切除率显着提高（50.0% 至 75.0%，p=0.007），而两组 IDS 的最佳切除率仍然很高（81.8% 与 81.3%，p>0.999）。 QC 后、先进的减灭程序以及与其他部门的合作在 IDS 中有所增加 (p<0.05)。术中/术后并发症发生率具有统计学可比性 (p>0.05)，而第 2 组术后住院时间显着缩短（17 天与 22 天，p=0.001）。 QC 后中位无复发生存期有所增加，但没有统计学意义（19.18 个月 vs. 25.38 个月，p=0.855）。通过 QC 计划，晚期卵巢癌的治疗策略和临床结果显着改善。系统质量控制监测计划应被视为常规监测，以获得更好的手术结果。© 2025。亚洲妇科肿瘤学会、韩国妇科肿瘤学会和日本妇科肿瘤学会。

We investigated the effect of our quality control (QC) program on the management strategy, completeness of the surgery, and clinical outcomes in advanced ovarian cancer.A retrospective review of medical records from January 2005 to December 2019 identified 129 patients with advanced ovarian cancer. Cases were categorized into group 1 (2005-2013) and group 2 (2014-2019) before and after implementation of the QC program. Comparisons included clinicopathological variables, operative details, recurrence and survival outcomes.In Group 2 (n=44), after QC program implementation, primary debulking surgery (PDS) decreased (87.1% vs. 63.6%) and interval debulking surgery (IDS) increased (12.9% vs. 36.4%), indicating a shift in surgical strategy. Optimal resection rates improved significantly for PDS in group 2 (50.0% to 75.0%, p=0.007) and remained high for IDS in both groups (81.8% vs. 81.3%, p>0.999). Post-QC, advanced debulking procedures and co-operation with other departments increased in the IDS (p<0.05). Intra/post-operative complication rates were statistically comparable (p>0.05), whereas postoperative hospital stay was significantly shorter in group 2 (17 days vs. 22 days, p=0.001). Median recurrence-free survival increased after QC, although not statistically significant (19.18 months vs. 25.38 months, p=0.855).With QC program, treatment strategies and clinical outcomes were significantly improved in advanced ovarian cancer. Systematic QC monitoring program should be considered as routine surveillance for better surgical outcomes.© 2025. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.